Ask AI
ProCE Banner Activity

SOHO-01: Phase I/II Study of Sevabertinib in Advanced HER2-Mutant NSCLC

Conference Coverage
Slideset

In the phase I/II SOHO-01 trial, sevabertinib induced durable responses in patients with advanced HER2-mutant NSCLC, including previously treated and untreated patient cohorts, with manageable toxicity.

Released: October 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly